Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office [Yahoo! Finance]
Cyclo Therapeutics, Inc. (CYTH)
Company Research
Source: Yahoo! Finance
biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) regarding Cyclo Therapeutics' U.S. Patent Application No. 17/289,137 titled, " Methods for Treating Alzheimer's Disease N. Scott Fine, CEO of Cyclo Therapeutics, commented, "This patent application allowance represents an important milestone for our Alzheimer's disease asset as well as a valuable component of our patent estate. With the desperate need for innovation and therapeutic solutions to treat early onset Alzheimer's disease, we remain hopeful in the potential for Cyclo Therapeutics' Trappsol ® Cyclo™ to play a significant role in the treatment armamentarium." About Cyclo Therapeutics Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through
Show less
Read more
Impact Snapshot
Event Time:
CYTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTH alerts
High impacting Cyclo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CYTH
News
- Cyclo Therapeutics, Inc. (NASDAQ: CYTH) is now covered by analysts at Ascendiant Capital Markets. They set a "buy" rating and a $2.60 price target on the stock.MarketBeat
- Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateBusiness Wire
- Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer's Disease [Yahoo! Finance]Yahoo! Finance
- Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s DiseaseBusiness Wire
CYTH
Sec Filings
- 3/18/24 - Form 10-K
- 3/4/24 - Form 8-K/A
- 2/15/24 - Form 4
- CYTH's page on the SEC website